- Research works
- 12 ▼ 17% vs 2018-21
- Citations
- 304 26.3 per fractional work
- Top-10% rate
- 11.5% all institutions 10.0%
- Open access
- 85% world 40%
- International
- 55% world 18%
Not ranked overall: Qserve Group (Netherlands) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which fields of science does Qserve Group (Netherlands) work in?
In all years, 49% of research at Qserve Group (Netherlands) is in Life Sciences, 46% in Health Sciences. Its largest fields are Medicine (46%), Biochemistry, Genetics and Molecular Biology (35%), Immunology and Microbiology (14%). It does 1.8× the world's share of Life Sciences.
Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.
Its 3 domains and 8 fields, with their numbers
- Life Sciences648.9%
- Health Sciences545.9%
- Medicine545.9%
- Physical Sciences15.2%
- Engineering03.7%
- Materials Science00.9%
- Environmental Science00.6%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Who are the top researchers at Qserve Group (Netherlands)?
Ranked on the quality score, Edward Dolk lead among researchers whose main affiliation is Qserve Group (Netherlands).
- 1
Edward Dolk
Netherlands · #750,745 worldwide 736 citations · 36 works
Which research topics does Qserve Group (Netherlands) publish most on?
By volume in 2022-now: Monoclonal and Polyclonal Antibodies Research, Antifungal resistance and susceptibility, Glycosylation and Glycoproteins Research and Viral Infectious Diseases and Gene Expression in Insects.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
- 2 Antifungal resistance and susceptibility Infectious Diseases 0 works
- 3 Glycosylation and Glycoproteins Research Molecular Biology 0 works
- 4 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 0 works
- 5 Chemokine receptors and signaling Oncology 0 works
- 6 Advanced Biosensing Techniques and Applications Molecular Biology 0 works
- 7 Complement system in diseases Immunology 0 works
- 8 Immunotherapy and Immune Responses Immunology 0 works
- 9 Immune Cell Function and Interaction Immunology 0 works
- 10 Receptor Mechanisms and Signaling Molecular Biology 0 works
How open and international is its research?
Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 40% of research is openly available.
World: 18% is written across borders.
How has Qserve Group (Netherlands)'s research output changed?
Output in 2022-2025 was 17% lower than in 2018-2021.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is Qserve Group (Netherlands) as a percentage of every work published that year, 0.000012% in 2024.
Fractional works of Qserve Group (Netherlands) over all fractional works that year. How the balance of science has shifted.
Other research institutions in Arnhem
- Rijnstate Hospital
- HAN University of Applied Sciences
- Kema International (Netherlands)
- Nederlands Instituut Publieke Veiligheid
- Cito (Netherlands)
- Radiotherapiegroep
- European Association of Urology
- Tennet (Netherlands)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.
Discussion
Ask a question or share a note about Qserve Group (Netherlands). Posts are plain text and can be reported.